BR0318269A - composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares - Google Patents

composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares

Info

Publication number
BR0318269A
BR0318269A BRPI0318269-0A BR0318269A BR0318269A BR 0318269 A BR0318269 A BR 0318269A BR 0318269 A BR0318269 A BR 0318269A BR 0318269 A BR0318269 A BR 0318269A
Authority
BR
Brazil
Prior art keywords
periocular
disorders
methods
targets
therapy
Prior art date
Application number
BRPI0318269-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Marcio Marc Abreu
Original Assignee
Marcio Marc Abreu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marcio Marc Abreu filed Critical Marcio Marc Abreu
Publication of BR0318269A publication Critical patent/BR0318269A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
BRPI0318269-0A 2003-04-24 2003-12-08 composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares BR0318269A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/421,956 US20040058313A1 (en) 2002-04-24 2003-04-24 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
PCT/US2003/038740 WO2004096183A1 (en) 2003-04-24 2003-12-08 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

Publications (1)

Publication Number Publication Date
BR0318269A true BR0318269A (pt) 2006-05-23

Family

ID=33415845

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318269-0A BR0318269A (pt) 2003-04-24 2003-12-08 composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares

Country Status (7)

Country Link
US (2) US20040058313A1 (https=)
EP (1) EP1622589B1 (https=)
JP (1) JP2006524185A (https=)
AU (1) AU2003297684A1 (https=)
BR (1) BR0318269A (https=)
CA (2) CA2523363C (https=)
WO (1) WO2004096183A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
ATE424187T1 (de) * 2002-07-15 2009-03-15 Alcon Inc Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
EP1824496A4 (en) * 2004-11-17 2008-07-16 Joanne Mclaurin COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
JP2007051090A (ja) * 2005-08-18 2007-03-01 Pharma Foods International Co Ltd 卵白ペプチドを有効成分として含有する血流改善剤
WO2007041855A1 (en) * 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
CN103054837A (zh) * 2006-03-09 2013-04-24 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
WO2008061373A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
CA2683546A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
WO2008124930A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
JP2010523602A (ja) 2007-04-12 2010-07-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
WO2010036937A1 (en) * 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US20120136011A1 (en) * 2010-07-30 2012-05-31 Allergan, Inc. Compounds and methods for skin repair
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
AU2012238954A1 (en) * 2011-04-07 2013-11-21 Sensimed Sa Device and method for detecting ophtalmic and/or brain diseases
CN105188733B (zh) 2013-03-13 2020-05-08 建新公司 包含pdgf和vegf结合部分的融合蛋白及其使用方法
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
JP7097070B2 (ja) 2015-10-01 2022-07-07 ゴレイニ インコーポレイテッド クロライドチャネルの標的発現及びその使用方法
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
US11096993B2 (en) 2016-12-08 2021-08-24 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
AU2018263853A1 (en) * 2017-05-01 2019-11-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treating ocular pathologies
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
CN112972444B (zh) * 2021-02-19 2022-07-26 中国医学科学院整形外科医院 美西律在制备治疗和/或预防面颈部皮肤皱纹的产品中的应用
CN113288784B (zh) * 2021-06-11 2023-03-31 中国人民解放军陆军军医大学第一附属医院 泪道冲洗收水装置
KR20260039752A (ko) 2023-07-13 2026-03-20 크리야 테라퓨틱스, 인크. 보체 경로 억제제 융합체 및 그의 사용 방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545260A (en) * 1967-10-31 1970-12-08 Technicon Corp Means and method for detection of glaucoma
US3585849A (en) * 1968-10-09 1971-06-22 American Optical Corp Method and apparatus for measuring intraocular pressure
US3724263A (en) * 1970-09-29 1973-04-03 Bio Optronics Inc Electrical digital display tonometer
US3963019A (en) * 1974-11-25 1976-06-15 Quandt Robert S Ocular testing method and apparatus
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4305399A (en) * 1978-10-31 1981-12-15 The University Of Western Australia Miniature transducer
CH633952A5 (fr) * 1980-03-14 1983-01-14 Grounauer Pierre Alain Dispositif de mesure des potentiels electriques de l'oeil.
US4485820A (en) * 1982-05-10 1984-12-04 The Johns Hopkins University Method and apparatus for the continuous monitoring of hemoglobin saturation in the blood of premature infants
US4734275A (en) * 1983-08-19 1988-03-29 Research Corporation Anti-curare agents
JPS61321A (ja) * 1984-06-12 1986-01-06 株式会社トプコン 非接触式眼圧計
US4629424A (en) * 1984-08-30 1986-12-16 Integrated Ionics, Inc. Intraoral ambient sensing device
US4771792A (en) * 1985-02-19 1988-09-20 Seale Joseph B Non-invasive determination of mechanical characteristics in the body
US4628938A (en) * 1985-12-09 1986-12-16 Lee David A Continuous applanation tonometer
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
JPS63267331A (ja) * 1986-12-27 1988-11-04 Tokyo Optical Co Ltd 非接触式眼圧計
US5076274A (en) * 1987-02-18 1991-12-31 Canon Kabushiki Kaisha Non-contact tonometer
US5183044A (en) * 1987-06-30 1993-02-02 Kabushiki Kaisha Topcon Noncontact type tonometer
US4922913A (en) * 1987-11-12 1990-05-08 Waters Jr George E Intraocular pressure sensor
US4860755A (en) * 1988-02-08 1989-08-29 Erath-Young Instrument Company, Inc. Differential pressure applanation tonometer
US5165409A (en) * 1988-08-23 1992-11-24 Coan William M Tonometry apparatus
US5005577A (en) * 1988-08-23 1991-04-09 Frenkel Ronald E P Intraocular lens pressure monitoring device
US4951671A (en) * 1988-08-23 1990-08-28 Coan William M Tonometry apparatus
US5217015A (en) * 1990-06-08 1993-06-08 Kaye David B Pressure sensing device having transducer overlying and deforming eye
US5109852A (en) * 1990-06-08 1992-05-05 Kaye David B Method for sensing pressure in an object
US5342283A (en) * 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5148807A (en) * 1990-08-28 1992-09-22 Ohio State University Non-contact tonometer
US5209231A (en) * 1990-11-02 1993-05-11 University Of Connecticut Optical glucose sensor apparatus and method
US5295495A (en) * 1991-05-13 1994-03-22 The Australian National University Glaucoma testing from observations of optokinetic nystagmus
US5251627A (en) * 1991-06-27 1993-10-12 Morris Donald E Non-invasive measurement of eyeball pressure using vibration
US5179953A (en) * 1991-08-27 1993-01-19 Jermik Systems, Ltd. Portable diurnal intraocular pressure recording system
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5375595A (en) * 1993-03-17 1994-12-27 The Regents Of The University Of Calif. Apparatus and method for non-contact, acoustic resonance determination of intraocular pressure
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US5830139A (en) * 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
JP2002521332A (ja) * 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
WO2000038667A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
ATE308510T1 (de) * 1999-12-08 2005-11-15 Warner Lambert Co Inhibitore der verzweigte-aminosäure-abhängigen aminotransferase und deren verwendung in der behandlung der zuckerkranke retinopathie
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin

Also Published As

Publication number Publication date
EP1622589B1 (en) 2017-03-15
WO2004096183A1 (en) 2004-11-11
CA2523363C (en) 2015-02-10
EP1622589A1 (en) 2006-02-08
AU2003297684A1 (en) 2004-11-23
US20040058313A1 (en) 2004-03-25
CA2523363A1 (en) 2004-11-11
US20120282242A1 (en) 2012-11-08
JP2006524185A (ja) 2006-10-26
CA2868648A1 (en) 2004-11-11
EP1622589A4 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BRPI0417493A (pt) terapia com toxina botulìnica para distúrbios da pele
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
BR0315630A (pt) Administração de combinação de uma indolinona com um agente quimioterapêutico para distúrbios de proliferação celular
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BR0315319A (pt) Terapias e procedimentos dentais com toxina botulìnica
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
WO2002018334A3 (en) Sodium channel modulators
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0415215A (pt) aplicação de um polifenol para o tratamento de uma lesão cancerosa ou pré-cancerosa da pele
BR0312696A (pt) Tratamento tópico de doenças da pele
BRPI0607536A2 (pt) tratamento de dor
BRPI0413083A (pt) métodos para tratar inflamação e doenças associadas com inflamação com uma estatina e éter
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 9/20, S61F 2/00, A61F 2/14, A61P 27/06

Ipc: A61K 9/20 (2011.01), A61F 2/00 (2011.01), A61F 2/1

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.